- ►fe-inzichten.nl [PDF] - Free from Publisher K Hermansen, M Colombo, H Storgaard, A … - Diabetes Care, 2002 - Am Diabetes Assoc RESULTS—The postprandial glycemic control with BIAsp 30, as assessed by the
5-h postmeal serum glucose excursion, was superior to that with both BHI 30 and
Mix25 (16.6 ± 4.5 vs. 20.1 ± 4.9 and 18.9 ± 6.1 mmol/l per hour, ... Cited by 87 - Related articles - BL Direct - All 11 versions
PT McSorley, PM Bell, LV Jacobsen, A … - Clinical therapeutics, 2002 - Elsevier Results: Total daily insulin exposure was similar between treatment periods.
Mean area under the total insulin concentration-time profile during the 2 hours
following administration of BIAsp 30 was 17% greater than that of BHI 30 ... Cited by 75 - Related articles - All 8 versions
BO Boehm, PD Home, C Behrend, NM Kamp, … - Diabetic Medicine, 2002 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 134 - Related articles - BL Direct - All 9 versions
C Weyer, T Heise, L Heinemann - Diabetes Care, 1997 - Am Diabetes Assoc OBJECTIVE: To study the pharmacodynamic properties of a 30/70 premixed
formulation of the rapid-acting insulin analog insulin aspart (B28Asp) and its
protamine-retarded preparation (30/70 IA) in comparison with a respective ... Cited by 81 - Related articles - BL Direct - All 6 versions
- ►ohio-state.edu [PDF] LV Jacobsen, B Søgaard, A Riis - European journal of clinical pharmacology, 2000 - Springer Abstract Objective: With the aim to obtain a premixed rapid-acting insulin with
a serum insulin pro®le more closely resembling the endogenous meal-stimulated
se- rum insulin pro®les, a 30/70 (rapid/intermediate-acting) premixed ... Cited by 97 - Related articles - BL Direct - All 7 versions
C Kilo, N Mezitis, R Jain, J Mersey, J McGill, … - Journal of diabetes and its complications, 2003 - Elsevier Transitioning safely to insulin therapy when oral antidiabetic agents fail to
provide adequate glycemic control is a critical aspect of care for the patient
with type 2 diabetes mellitus (T2DM). We evaluated the clinical ... Cited by 65 - Related articles - All 9 versions
AJ Garber, J Wahlen, T Wahl, P Bressler, R … - Diabetes Obesity and Metabolism, 2006 - epgonline.com Methods: Enrolled patients (n ¼ 100, HbA1c !7.5 and 10%) were !18 years of age,
had diabetes !12 months and had received a stable antidiabetic regimen for at
least 3 months [minimum of two oral antidiabetic drugs (OADs) or at least ... Cited by 141 - Related articles - View as HTML - BL Direct - All 10 versions
JS Christiansen, JA Vaz, Z Metelko, M Bogoev … - Diabetes Obesity and Metabolism, 2003 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 58 - Related articles - BL Direct - All 7 versions
L Niskanen, LE Jensen, J Råstam, L Nygaard … - Clinical therapeutics, 2004 - Elsevier Results: A total of 137 patients were randomized to treatment; 4 were withdrawn
during the 2-week run-in treatment with biphasic human insulin 30. The mean (SD)
characteristics of the remaining 133 patients (79 men, 54 women) were as ... Cited by 52 - Related articles - All 3 versions
BO Boehm, JA Vaz, L Brøndsted, PD Home - European journal of internal medicine, 2004 - Elsevier No significant difference was found in mean HbA 1c after 24 months [BIAsp30,
8.35±0.20%; BHI30 8.13±0.16%; adjusted mean difference (BIAsp30−BHI30) 0.03
(90% CI −0.29 to 0.34)%, P=0.89]. The proportion of patients experiencing ... Cited by 65 - Related articles - All 6 versions
